LETTER TO THE EDITOR
|Year : 2020 | Volume
| Issue : 3 | Page : 395-397
Autosomal recessive spastic ataxia of charlevoix-saguenay (ARSACS): Case report of a novel nonsense mutation in the SACS gene
Ayush Agarwal1, Divyani Garg2, Akash Kharat1, Abdul Qavi1
1 Department of Neurology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
2 Department of Neurology, Lady Hardinge Medical College, New Delhi, Delhi, India
|Date of Submission||16-Dec-2019|
|Date of Acceptance||30-Dec-2019|
|Date of Web Publication||09-May-2020|
Dr. Abdul Qavi
Department of Neurology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Agarwal A, Garg D, Kharat A, Qavi A. Autosomal recessive spastic ataxia of charlevoix-saguenay (ARSACS): Case report of a novel nonsense mutation in the SACS gene. Ann Indian Acad Neurol 2020;23:395-7
|How to cite this URL:|
Agarwal A, Garg D, Kharat A, Qavi A. Autosomal recessive spastic ataxia of charlevoix-saguenay (ARSACS): Case report of a novel nonsense mutation in the SACS gene. Ann Indian Acad Neurol [serial online] 2020 [cited 2022 Aug 18];23:395-7. Available from: https://www.annalsofian.org/text.asp?2020/23/3/395/284072
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an autosomal recessive neurodegenerative disorder characterized by a triad of early onset cerebellar ataxia, spasticity, and sensorimotor polyneuropathy (distal muscle wasting with finger and foot deformities). Dysarthria, nystagmus, and retinal hypermyelination may sometimes be observed. It was first described by Bouchard et al. in1978 as an uncommon cause of autosomal recessive cerebellar ataxia., Although initially thought to be prevalent only in Canada, it has now been increasingly reported from rest of the world. Exome sequencing studies identified multiple causative mutations in the sacsin molecular chaperone gene (SACS) on chromosome 13q. However, new pathogenic mutations continue to be identified. We report a patient with typical clinical and imaging features of ARSACS, where targeted SACS gene testing lead to the discovery of a novel pathogenic SACS mutation.
A 28-years-old male, born of non-consanguineous marriage, presented with progressive gait ataxia and recurrent falls from 3 years of age. He also developed dysarthria and lower limb stiffness at 10 years of age, followed by thinning of feet. Family history was negative. On examination, he had bilateral pes cavus with hammer toes. Neurological examination revealed lower limb spasticity, brisk reflexes, and extensor plantar response. Sensory and fundus examination were normal. He also exhibited dysmetria, dysdiachokinesia, nystagmus, and cerebellar gait. He had no Kayser-Fleischer ring More Details, telengiectasias, or tendon xanthomas. Systemic examination was normal. Diagnosis of an autosomal recessive ataxia syndrome was made and patient evaluated along those lines.
MRI brain revealed superior cerebellar vermian atrophy and T2 linear “striped” hypointensities in pons [Figure 1]a and [Figure 1]b. Nerve conduction studies (NCS) demonstrated prolonged distal latencies with decreased velocities in motor nerves of all limbs while sensory NCS was not recordable. ARSACS and Refsum's disease are the ataxia syndromes associated with predominant demyelinating neuropathy. Genetic testing for Friedreich's ataxia and Spinocerebellar ataxia was negative. 2D-Echocardiography, serum albumin, lipid profile, and alpha fetoprotein were normal. Clinical exome (targeted SACS gene) sequencing revealed a heterozygous pathogenic non-sense mutation on exon 10 of SACS gene (C,4232T > G) resulting in a stop codon and premature truncation of the protein. Another mutation of uncertain significance was found on the same exon (C,8132C > T).
|Figure 1: MRI brain T2 weighted image revealing superior cerebellar vermian atrophy (a) and linear “striped” hypointensities in pons (b)|
Click here to view
ARSACS is an early onset, cerebellar ataxia first described from Quebec, Canada in 1978. Canadian patients formed a majority of these cases initially, but an increasing number have been described from other countries as well, possibly pointing toward an earlier underdiagnosis. Many of these cases were initially diagnosed as spastic diplegia type of cerebral palsy. Approximately 30 mutations in the SACS gene have been reported and newer ones are being continuously discovered.
It usually presents in early childhood (12 months to 5.5 years of age) and diagnosis is based on typical clinical manifestations (cerebellar ataxia with spasticity and peripheral neuropathy) and radiological findings (superior vermian atrophy and pontine linear T2/FLAIR hypo-intensities on T2/FLAIR). Confirmation of diagnosis is done by demonstration of pathogenic mutations in the sacsin gene located on chromosome 13q.
The cardinal clinical features of ARSACS are gait instability with frequent falls, both of which were present in our patient. The disease progression is slow with patients becoming wheelchair bound around the third to fourth decade of life. The initial features are a combination of early onset cerebellar signs like ataxia, dysarthria, and nystagmus, with pyramidal signs in the lower limbs like spasticity, hyperreflexia and extensor plantar response. Lower limb sensorimotor peripheral neuropathy tends to develop later in the disease course causing distal atrophy, pes cavus, and hammer toes. These findings were present in our patient.
Fundoscopy may reveal hypermyelinated nerve fibres radiating from the optic disc in some patients and cognition tends to be preserved. Both fundoscopy and cognition was normal in our patient.
Imaging findings described on MRI brain include early and progressive superior cerebellar vermian atrophy with the inferior vermis remaining preserved throughout. However, global cerebral atrophy may occur later in the disease course. Linear T2 and FLAIR hypo-intensities have also been described. Cerebral white matter remains preserved throughout. All these findings were present in our patient.
The causal mutations in the SACS gene vary between individuals. The founder mutations discovered from Quebec were a single-base deletion at position 6594 (6594delT) and a nonsense mutation 5254C > T. Approximately 95% Canadian patients harbor these mutations. Several novel mutations have been described with some variations in the disease phenotype. The absence of abnormal myelinated retinal fibres in our patient is probably explained by the same.
ARSACS must be suspected in early onset cerebellar ataxia combined with spasticity and peripheral neuropathy. Typical radiological features such as superior cerebellar vermian atrophy and linear pontine hypo-intensities greatly enhance the diagnosis. Ultimately, the diagnosis is confirmed by genetic studies. We describe such a case from India, and also demonstrate the occurrence of a novel pathogenic nonsense mutation in the SACS gene.
Ethical compliance statement
The study complied with all Ethical standards and did not require the consent of the Institutional Ethics Committee.
Written informed patient consent was taken.
All authors have read and complied with the journal's ethical publication guidelines.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| Appendix 1:|| |
| References|| |
Martin MH, Bouchard JP, Sylvain M, St-Onge O, Truchon S. Autosomal recessive spastic ataxia of Charlevoix-Saguenay: A report of MR imaging in 5 patients. AJNR Am J Neuroradiol 2007;28:1606-8.
Bouchard JP, Barbeau A, Bouchard R, Bouchard RW. Electromyography and nerve conduction studies in Friedreich's ataxia and Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Can J Neurol Sci 1979;6:185-9.
Duquette A, Brais B, Bouchard JP, Mathieu J. Clinical presentation and early evolution of spastic ataxia of Charlevoix-Saguenay. Mov Disord 2013;28:2011-4.
Engert JC, Bérubé P, Mercier J, Doré C, Lepage P, Ge B, et al
. ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutation in a new gene encoding an 11.5-Kb ORF. Nat Genet 2000;24:120-5.
Ogawa T, Takiyama Y, Sakoe K, Mori K, Namekawa M, Shimazaki H, et al
. Identification of a SACS gene missense mutation in ARSACS. Neurology 2004;62:107-9.
Gomez CM. ARSACS goes global. Neurology 2004;62:10-11.
Takiyama Y. Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Neuropathology 2006;26:368-75.
Embirucıu EK, Martyn ML, Schlesinger D, Kok F. Autosomal recessive ataxias: 20 types and counting. Arq Neuropsiquiatr 2009;67:1143-56.
El Euch-Fayache G, Lalani I, Amouri R, Turki I, Ouahchi K, Hung WY, et al
. Phenotypic features and genetic findings in sacsin-related autosomal recessive ataxia in Tunisia. Arch Neurol 2003;60:982-8.
Mercier J, Prevost C, Engert JC, Bouchard JP, Mathieu J, Richter A. Rapid detection of the sacsin mutations causing autosomal recessive spastic ataxia of Charlevoix-Saguenay. Genet Test 2001;5:255-9.
|This article has been cited by|
||Genetics of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Role of Sacsin in Neurodegeneration
| ||Jaya Bagaria, Eva Bagyinszky, Seong Soo A. An |
| ||International Journal of Molecular Sciences. 2022; 23(1): 552 |
|[Pubmed] | [DOI]|